Posted By
Tags
- 50 Years
- 5 Years
- 7
- 7 Years
- A
- Accelerated
- Accompaniment
- Acetate
- Acro
- Across
- Adaptive Behavior
- Adaptive immune system
- Advancing
- Adverse
- Adverse effect
- Adverse event
- Adverse Events
- Ageing
- Aging
- AIM
- Alexion
- Alexion Pharmaceuticals
- Amgen
- Amy Perrin
- An
- Annual general meeting
- APN
- Association
- Audience
- Bad News
- Bailter Space
- Balance
- Banner
- B cell
- Being
- Being Erica
- Benefit
- Beta
- Betas
- Bristol Myer
- Bristol-Myers Squibb
- Cancer
- Capacity
- Care
- Celgene
- Center, Indiana
- Centers
- Cession
- Chamber music
- Characteristic
- Choice
- Clarification
- Clinical
- Clinical trial
- Clinical Trials
- CMSC
- Coincidence
- Comorbidity
- Complex
- Comprehensive
- Concern
- Conducting
- Confident
- Consideration
- Consortium
- Continuing
- Coordinator
- COVID-19
- Covid-19 pandemic
- Coyle
- Decisions
- Decline
- De-escalation
- Degree
- Demographic profile
- Dependent and independent variables
- Differences
- Disappeared
- Discontinuation
- Disease
- Disease progression
- DMT
- DMTS
- D.O.E.
- DR
- Dreamcar
- Drug
- Drug efficacy
- Duration
- EDSS
- Effect
- Efficacy
- Eli Lilly
- E.M.D.
- End-of-life
- Essential
- Every
- Evidence
- Expanded Disability Status Scale
- Expansion
- Factor
- Female
- Finance
- FOCAL
- Focus
- Follow-up
- Framed
- French
- Fumaric acid
- Funding of science
- Genentech
- General population
- Genzyme
- Glatiramer acetate
- GlaxoSmithKline
- GOE
- Goes
- Gone
- Greater
- Hand
- Harm
- Health
- Height
- Helping behavior
- Her
- High Risk
- Horizon
- If
- Illinois
- Immune
- Immune system
- Immunoglobulin G
- Immunosenescence
- I'm Talking
- Incidence
- Include
- Infection
- Inflammatory
- Injection
- Interferon
- Interferon type I
- Intrinsic and extrinsic properties
- Keep
- LabCorp
- Lesion
- Less
- Leukoencephalopathy
- Levels
- Likelihood function
- Lilly Mylan
- Literature
- LoCash
- Long A
- M
- Match
- Maywood
- Maywood, Illinois
- M.D.
- Me and I
- Medical
- Medical Center
- Medication
- Medscape
- Mention
- Merck Serono
- Meta-analysis
- Mind
- Mixed
- Modifier
- Most
- Most important
- Mri
- MSN
- Multiple sclerosis
- Myer
- Myers Squibb
- My Mind
- Nashville
- Nashville, Tennessee
- National Institute of Neurological Disorders and Stroke
- Need
- Network
- Neurology
- Neuroscience
- Never
- New
- New York
- No
- Normal
- Noted
- Novartis
- Offering
- Older
- Onset
- Option
- Originally
- Over
- Pandemic
- Pat Coyle
- Patient
- Patient choice
- Perrin Ross
- Pharmaceutical drug
- Phase
- Physician
- Population
- Preferred
- Presentation
- Presenting
- Prevalence
- Pro
- Professional
- Professional network service
- Program coordinator
- Progression
- Progressive
- Progressive lens
- Progressive multifocal leukoencephalopathy
- Prompt
- PROS
- Pros & Cons
- Protection
- Q&A
- Q&a session
- Questioning
- Randomized experiment
- Randomness
- Range
- Ranking
- Reaction
- Recommendation
- Recover
- Reduction
- Reductions
- Registry
- Relapse
- Relationship
- Research
- Respect
- Result
- Retrospective
- Retrospective cohort study
- Risk
- Risk of infection
- Roche Sandoz
- Ross Ha
- Safety
- Sandoz
- Sanofi
- Scale
- Sclerosis
- Score
- Scores
- Second
- Serono
- Serum
- Session
- Session One
- Sex
- Shorter
- Shown
- Situations
- So long
- Some
- Sometimes
- Specialist
- Stable
- Stay
- Stony Brook
- Stony Brook, New York
- Stony Brook University
- Stony Brook University Hospital
- Stop-loss policy
- Studie
- Success
- Survey
- Syphon Filter
- Tell Me
- Tennessee
- Teriflunomide
- The age
- The balance
- The general
- The M's
- Then
- The other
- Therapy
- The Relapse
- These People
- The way
- Things
- Think
- T.I.P.
- Transition
- Treat
- Treating
- Treatment outcomes
- Trial
- Trials
- UCB
- University
- University Medical Center
- Versus
- Wellness
- What
- What Would the Community Think
- When
- Who
- Will I?
- Wonder
- Yes
- Younger